Outlook Therapeutics (OTLK) Income from Continuing Operations (2015 - 2026)
Outlook Therapeutics (OTLK) reported Income from Continuing Operations of 4453081.0 for Q1 2026, up 90.39% year-over-year from 2338876.96 in Q1 2025, and up 66.97% quarter-over-quarter from 13483952.0 in Q4 2025.
Outlook Therapeutics (OTLK) Income from Continuing Operations (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has 12 years of Income from Continuing Operations data on file, last reported at 4453081.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 4453081.0, up 90.39% year-over-year; the trailing twelve-month figure through Mar 2026 was 51382304.0 (down 187.64% YoY), and the FY2025 annual result was 62424863.0, up 17.17% from the prior year.
- Income from Continuing Operations climbed to 4453081.0 in Q1 2026 per OTLK's latest filing, from 13483952.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 44409187.0 in Q2 2024 and troughed at 114288943.0 in Q1 2024.
- A 5-year average of 17732686.88 and a median of 14345025.0 in 2022 frame the typical range for Income from Continuing Operations.
- On a YoY basis, Income from Continuing Operations climbed as much as 314.8% in 2024 and fell as far as 1617.52% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 15688028.0 in 2022, then surged by 34.2% to 10323122.0 in 2023, then tumbled by 109.31% to 21606852.0 in 2024, then surged by 37.59% to 13483952.0 in 2025, then jumped by 66.97% to 4453081.0 in 2026.
- Business Quant data shows OTLK's Income from Continuing Operations at 4453081.0 in Q1 2026, 13483952.0 in Q4 2025, and 13292769.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.48 Mn |
| 10 | Outlook Therapeutics | 51.56 Mn | 43.81 Mn | -21,888.00 | -4.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.45 Mn |
| Dec 31, 2025 | -13.48 Mn |
| Sep 30, 2025 | -13.29 Mn |
| Jun 30, 2025 | -20.15 Mn |
| Mar 31, 2025 | -46.36 Mn |
| Dec 31, 2024 | -21.61 Mn |
| Sep 30, 2024 | 5.69 Mn |
| Jun 30, 2024 | 44.41 Mn |
| Mar 31, 2024 | -114.29 Mn |
| Dec 31, 2023 | -10.32 Mn |
| Sep 30, 2023 | -12.99 Mn |
| Jun 30, 2023 | -20.68 Mn |
| Mar 31, 2023 | -6.65 Mn |
| Dec 31, 2022 | -15.69 Mn |
| Sep 30, 2022 | -14.35 Mn |
| Jun 30, 2022 | -17.54 Mn |
| Mar 31, 2022 | -19.70 Mn |
| Dec 31, 2021 | -13.15 Mn |
| Sep 30, 2021 | -13.40 Mn |
| Jun 30, 2021 | -12.20 Mn |